Drug Trial Radar · NCT01148576
Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
Last checked: Nov 20, 2026Latest source record: Jun 22, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jun 2010
Primary completion
Dec 2011
Study completion Feb 2012
Sponsor
- Lead sponsor
- Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the influence of hepatic steatosis on the anti-viral effect of entecavir in chronic hepatitis B patients.
Conditions
- Chronic Hepatitis B
- Hepatic Steatosis
Interventions
entecavirDrug
entecavir 0.5 mg qd for 12 months
entecavirDrug
entecavir 0.5 mg qd for 12 months
essentiale + entecavirDrug
entecavir 0.5 mg qd for 12 months,Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
Vitamin E + entecavirDrug
entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Differences in the anti-viral effect of entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first affiliated hospital, college of medicine, zhejiang university
Hangzhou, Zhejaing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.